Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Core Insights - Jazz Pharmaceuticals is showcasing its advancements in oncology research at two major conferences: the 2024 San Antonio Breast Cancer Symposium (SABCS) and the 66th Annual American Society of Hematology (ASH) Annual Meeting [1][3] - The company will present significant data on its drug Ziihera® (zanidatamab-hrii), which has recently received FDA approval for treating HER2-positive biliary tract cancer [3][10] - Jazz is committed to improving treatment outcomes for patients with challenging HER2-positive cancers through ongoing clinical trials [3][9] SABCS Presentations - Jazz will present a trial-in-progress poster for the Phase 3 EmpowHER303 trial, comparing zanidatamab with trastuzumab in patients with metastatic HER2-positive breast cancer [2] - A spotlight presentation will feature new data from a Phase 1b/2 study of zanidatamab combined with evorpacept in patients with pre-treated HER2-positive and HER2-low metastatic breast cancer [2] ASH Presentations - At ASH 2024, Jazz will highlight 13 abstracts focusing on oncology research, emphasizing its dedication to enhancing standards of care in blood cancers and hematologic diseases [3] - Key presentations will include a randomized comparison of Vyxeos® (daunorubicin and cytarabine) in high-risk acute myeloid leukemia patients [4][25] Ziihera® Overview - Ziihera is a bispecific HER2-directed antibody that targets two extracellular sites on HER2, leading to tumor growth inhibition and cell death [8] - The drug is indicated for adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer, with FDA approval based on overall response rates [8][10] Development and Designations - Ziihera has received Breakthrough Therapy designation for HER2 gene-amplified biliary tract cancer and Fast Track designations for other indications [10] - The drug is being developed in collaboration with BeiGene, under license from Zymeworks, and is part of a broader clinical program aimed at solid tumors expressing HER2 [9][10]